{"schema_version":"1.0","type":"article","title":"Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.md","lang":"en","date":"2026-07-25","publish_at":"2026-07-25T09:20:00+08:00","updated_at":"2026-07-25","category":"商業分析系列","topic":"商業分析系列","tags":["Roche","Big Pharma","pharma strategy","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","BRIM Biotechnology","BD licensing","drug development","biotech valuation","Taiwan biotech"],"summary":"Roche generated CHF 47.669 billion in pharmaceutical sales in 2025, with Ocrevus, Hemlibra, and Vabysmo already accounting for roughly one-third of the total. The number that matters is not simply 19 potential new molecules, but whether giredestrant, fenebrutinib, obesity, Alzheimer's, and protein-degradation assets can inherit Roche's existing clinical, diagnostic, and commercial infrastructure on time.","key_points":[],"facts":[],"sections":["01 | The Transformation Has Already Happened. The Income Statement Said So First.","02 | The Two Legs Closest to the Finish: Giredestrant and Fenebrutinib","03 | The Next Layer of Options: Obesity, Alzheimer's, and BTK Degradation","04 | Roche's Most Valuable Asset Is the Time It Does Not Need to Spend Rebuilding a Market","05 | A Taiwan Comparison: Can BRIM Biotechnology Hand Ophthalmology Assets to a Mature Channel?","Conclusion | Roche's Deepest Moat Is Preventing the Revenue Baton From Being Dropped","References","Disclaimer"],"references":[{"title":"[Roche","source":"Full-year results 2025]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-01-29"},{"title":"[Roche","source":"FDA grants priority review to giredestrant in early breast cancer]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-06-02"},{"title":"[Roche","source":"FDA accepts giredestrant application in advanced breast cancer]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-02-20"},{"title":"[Roche","source":"Third pivotal fenebrutinib phase 3 study meets primary endpoint]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-03-02"},{"title":"[Roche","source":"Complete phase 3 efficacy and safety data for fenebrutinib]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-04-21c"},{"title":"[Roche","source":"Agreement with Nurix for bexobrutideg]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-06-08"},{"title":"[Roche","source":"Petrelintide transaction terms]","date":"","url":"https://www.roche.com/media/releases/med-cor-2025-03-12"},{"title":"[Roche","source":"Petrelintide phase 2 results]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-03-05"},{"title":"[Roche","source":"2026 ADA obesity pipeline update]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-06-01"},{"title":"[Roche","source":"2026 AAIC Alzheimer's and diagnostics update]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-07-07"},{"title":"[Roche","source":"Pharma Day 2025 pipeline and pre-2030 launch potential]","date":"","url":"https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf"},{"title":"[Roche","source":"Pharmaceutical pipeline]","date":"","url":"https://www.roche.com/solutions/pipeline"},{"title":"[BRIM Biotechnology","source":"Company and research model]","date":"","url":"https://www.brimbiotech.com/en/"},{"title":"[BRIM Biotechnology","source":"Development milestones]","date":"","url":"https://www.brimbiotech.com/about-us/milestone"}],"images":[{"alt":"Roche's established products hand clinical and commercial infrastructure to the next generation of medicines","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-01-en.webp"},{"alt":"Roche's near-term filings, mid-term phase 3 programs, and longer-term options form a three-layer succession map","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-02-en.webp"},{"alt":"Roche reuses clinical trials, diagnostics, physician networks, and commercial channels across six disease areas","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-04-en.webp"},{"alt":"BRIM Biotechnology's four ophthalmology assets face a prove, license, and scale succession test","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-03-en.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/cover-en.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-25）。Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle。https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-25-roche-19-molecule-succession-engine.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}